Valneva SE (VLA.PA)

3,7200 +0,0100 (+0,27%) Alla chiusura: 05:35PM CEST

Valneva SE

6 rue Alain Bombard
Saint-Herblain 44800
France
33 2 28 07 37 10
https://valneva.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 676

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Thomas Lingelbach	President, CEO & Director	919,56k	N/D	1963
Mr. Peter Buhler	Chief Financial Officer	558,83k	N/D	1971
Mr. Frederic Jacotot	VP of Legal & IP, General Counsel, and Corporate Secretary	305,2k	N/D	1964
Mr. Franck Grimaud MBA	Chief Business Officer	401,34k	N/D	1967
Dr. Juan-Carlos Jaramillo M.D.	Chief Medical Officer	539,76k	N/D	1972
Ms. Dipal Patel	Chief Commercial Officer	516,75k	N/D	1975
Mr. Vincent Dequenne	Chief Operating Officer	N/D	N/D	1967
Mr. Joshua Drumm Ph.D.	Vice President of Investor Relations	N/D	N/D	N/D
Ms. Laetitia Bachelot-Fontaine	VP of Global Communications & European Investor Relations	N/D	N/D	N/D
Ms. Petra Pesendorfer	Chief People Officer	N/D	N/D	1986

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

Governance aziendale

L'ISS Governance QualityScore di Valneva SE al 1 aprile 2024 è 9. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 7; diritti degli azionisti: 9; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.